SATSUMA PHARMACEUTICALS, INC. (STSA): Price and Financial Metrics
GET POWR RATINGS... FREE!
STSA Stock Price Chart Interactive Chart >
STSA Price/Volume Stats
| Current price | $3.42 | 52-week high | $7.48 |
| Prev. close | $3.20 | 52-week low | $2.51 |
| Day low | $3.03 | Volume | 55,200 |
| Day high | $3.48 | Avg. volume | 62,213 |
| 50-day MA | $3.65 | Dividend yield | N/A |
| 200-day MA | $4.56 | Market Cap | 107.89M |
SATSUMA PHARMACEUTICALS, INC. (STSA) Company Bio
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.
Latest STSA News From Around the Web
Below are the latest news stories about Satsuma Pharmaceuticals Inc that investors may wish to consider to help them evaluate STSA as an investment opportunity.
Satsuma Pharmaceuticals (STSA) Gets a Hold Rating from Leerink PartnersIn a report issued on December 17, Marc Goodman from Leerink Partners maintained a Hold rating on Satsuma Pharmaceuticals (STSA – Research Report), with a price target of $5.00. The company's shares closed last Wednesday at $4.65. According to TipRanks.com, Goodman is a 2-star analyst with an average return of 0.1% and a 42.5% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Avadel Pharmaceuticals. Currently, the analyst consensus on Satsuma Pharmaceuticals is a Moderate Buy with an average price target of $10.00. |
Short Interest in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Drops By 17.7%Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) saw a large decline in short interest in November. As of November 30th, there was short interest totalling 373,400 shares, a decline of 17.7% from the November 15th total of 453,900 shares. Currently, 1.7% of the shares of the stock are short sold. Based on an average daily trading volume, of […] |
Goldman Sachs Group Inc. Increases Holdings in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA)Goldman Sachs Group Inc. lifted its position in shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) by 27.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,930 shares of the financial services providers stock after acquiring an additional 4,721 shares during the quarter. Goldman [] The post Goldman Sachs Group Inc. Increases Holdings in Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) appeared first on ETF Daily News . |
Millennium Management LLC Acquires 126,853 Shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA)Millennium Management LLC grew its holdings in shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) by 849.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 141,783 shares of the financial services providers stock after acquiring an additional 126,853 shares during the quarter. [] |
Insider Buying: Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Major Shareholder Buys 2,922 Shares of StockSatsuma Pharmaceuticals, Inc. (NASDAQ:STSA) major shareholder Commodore Capital Lp purchased 2,922 shares of the businesss stock in a transaction dated Wednesday, November 24th. The shares were purchased at an average cost of $5.42 per share, for a total transaction of $15,837.24. The transaction was disclosed in a document filed with the SEC, which can be [] |
STSA Price Returns
| 1-mo | -12.98% |
| 3-mo | -18.57% |
| 6-mo | -30.06% |
| 1-year | -34.48% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -24.00% |
| 2021 | -2.39% |
| 2020 | -76.58% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...